1-乙基环丙烷-1-胺盐酸盐 | 174886-06-7

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-乙基环丙烷-1-胺盐酸盐
• 英文名称: 1-ethylcyclopropylamine hydrochloride
• 英文别名: 1-Ethylcyclopropan-1-amine hydrochloride；1-ethylcyclopropan-1-amine;hydrochloride
• CAS: 174886-06-7
• 化学式: C₅H₁₁N*ClH
• mdl: MFCD26959624
• 分子量: 121.61
• InChiKey: ZNYVZBCRYLJGFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.64
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-乙基环丙烷-1-胺盐酸盐 、 3-(6-(((3S,4S)-1-(tert-butoxycarbonyl)-4-fluoropiperidin-3-yl)amino)-3,5-difluoropyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxylic acid 在 1-丙基磷酸酐 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl (3S,4S)-3-((6-(7-((1-ethylcyclopropyl)carbamoyl)imidazo[1,2-a]pyridin-3-yl)-3,5-difluoropyridin-2-yl)amino)-4-fluoropiperidine-1-carboxylate
  参考文献：
  名称：

  WO2023/150601

  摘要：

  公开号：

文献信息

• [EN] SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B<br/>[FR] SULFAMOYL-ARYLAMIDES ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS DANS LE TRAITEMENT DE L'HÉPATITE B
  申请人：JANSSEN R & D IRELAND

  公开号：WO2014033170A1

  公开（公告）日：2014-03-06

  Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  乙肝病毒复制抑制剂，包括式(I)及其立体异构体、盐、水合物、溶剂化物，其中B、R1、R2和R4的含义如本文所述。本发明还涉及包含这些抑制剂的药物组合物及其用途，单独使用或与其他乙肝病毒抑制剂联合使用，用于乙肝治疗。
• [EN] TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLO EN TANT QU'INHIBITEURS DE PDE10
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013178572A1

  公开（公告）日：2013-12-05

  The present invention provides compounds of formula (Ia) and (Ib) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

  本发明提供了式(Ia)和(Ib)的化合物，其中R1、R2、R3和R4如说明书和权利要求中所定义，以及其生理上可接受的盐。这些化合物抑制PDE10A，可用作药物。
• NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20180009818A1

  公开（公告）日：2018-01-11

  The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R 2 , and X are as defined in the specification; or a salt thereof.

  本发明要解决的问题是提供一种具有RET抑制活性的新型化合物。本发明还提供了一种药物制剂，基于RET抑制活性，用于预防和/或治疗与RET相关的疾病，特别是癌症。本发明提供了一种由以下式表示的化合物：其中A、R2和X如规范中定义；或其盐。
• SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：US20150266890A1

  公开（公告）日：2015-09-24

  Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R 1 , R 2 and R 4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  公式（I）的乙型肝炎病毒复制抑制剂，包括立体化学同分异构体形式和其盐、水合物、溶剂化物，其中B、R1、R2和R4的含义如此处所定义。本发明还涉及制备该类化合物的过程，含有它们的药物组合物以及它们的用途，单独或与其他乙型肝炎病毒抑制剂联合使用，用于乙型肝炎疗法。
• NOVEL CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3269370A1

  公开（公告）日：2018-01-17

  The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I) : wherein A, R2, and X are as defined in the specification; or a salt thereof.

  本发明要解决的问题是提供一种具有 RET 抑制活性的新型化合物。本发明还提供了一种基于 RET 抑制活性的药物制剂，可用于预防和/或治疗 RET 相关疾病，特别是癌症。本发明提供了一种由式（I）代表的化合物： 其中 A、R2 和 X 如说明书中所定义；或其盐。